Page last updated: 2024-08-18

pyrroles and orantinib

pyrroles has been researched along with orantinib in 92 studies

Research

Studies (92)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	63 (68.48)	29.6817
2010's	29 (31.52)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blake, RA; Fong, TA; Hawtin, R; Hirth, KP; Hubbard, SR; Laird, AD; Liang, C; McMahon, G; Mohammadi, M; Schlessinger, J; Shawver, LK; Shenoy, N; Strawn, LM; Sun, L; Tang, C; Tang, F; Thurnher, A; Ullrich, A; Vajkoczy, P	1
Albitar, M; Cherrington, JM; Giles, FJ; Smolich, BD; West, KA; Yuen, HA	1
Bucana, CD; Davis, DW; Drazan, KE; Ellis, LM; Liu, W; McConkey, DJ; McMahon, G; Ogura, Y; Reinmuth, N; Shaheen, RM; Tseng, WW; Vellagas, R; Wieczorek, AA	1
Honsawek, S; Kiewlich, D; Krystal, GW; Liang, C; Lipson, KE; McMahon, G; Sun, L; Vasile, S	1
Ahmad, SA; Bucana, CD; Ellis, LM; Fan, F; Gallick, GE; Jung, YD; Liu, W; McMahon, G; Reinmuth, N; Shaheen, RM	1
Kuwano, M; Ono, M	1
Bucana, CD; Ellis, LM; Gallick, GE; Jung, YD; McConkey, DJ; McMahon, G; Solorzano, CC	1
Cherrington, JM; Knox, SJ; Laird, D; Ning, S	1
Fabbro, D; Manley, PW	1
Blanke, CD; Corless, CL; Druker, BJ; Heinrich, MC	1
Cherrington, JM; Griffin, RJ; Park, H; Song, CW; Wild, R; Williams, BW	1
Carver, J; Cherrington, JM; Christensen, JG; Laird, AD; Li, G; Louie, SG; Mendel, DB; Moss, KG; Smith, K; Xin, X	1
Issekutz, AC; Zhang, H	1
Gorelik, E; Huang, X; Laird, AD; Watkins, S; Wolf, SF; Wong, MK; Yi, H	1
Adams, A; Asad, Y; Cropp, G; Judson, I; O'Donnell, A; Raynaud, F; Workman, P	1
Barraja, P; Beall, HD; Bunderson, M; Moody, CJ; Newsome, JJ; Swann, E; Tooke, JE; Whatmore, JL	1
Ellis, LM	1
Alileche, A	1
Bergers, G; Bergsland, E; Hanahan, D; Meyer-Morse, N; Song, S	1
Abdollahi, A; Debus, J; Hahnfeldt, P; Han, X; Hlatky, L; Howlett, AR; Huber, PE; Krempien, R; Lipson, KE; Trinh, T; Weber, KJ	1
Ledbetter, S; Pratt, BM; Teicher, BA; Walter-Yohrling, J	1
Hasselbalch, HC	1
Caniatti, M; Cherrington, JM; Colombo, T; Garofalo, A; Ghilardi, C; Ghisleni, G; Giavazzi, R; Manenti, L; Naumova, E; Nicoletti, MI; Scanziani, E	1
Erber, R; Groth, G; Hammes, HP; Katsen, AD; Kerger, H; Menger, MD; Thurnher, A; Ullrich, A; Vajkoczy, P	1
Abrams, T; Calderan, L; Crescimanno, C; Degrassi, A; Farace, P; Giusti, A; Marzola, P; Murray, L; Nicolato, E; Osculati, F; Pesenti, E; Sbarbati, A; Terron, A	1
Cao, C; Choy, H; Donnelly, E; Geng, L; Hallahan, DE; Lu, B; McMahon, G; Musiek, A; Tan, J	1
Bruns, CJ; Guba, M; Jauch, KW; Kleespies, A	1
Abbruzzese, JL; Charnsangavej, CA; Davis, D; Faria, SC; Herbst, R; Hess, K; Hicks, M; Jackson, EF; Madden, T; McConkey, D; Scholz, C; Xiong, HQ	1
Evan, GI; Fox, SB; Harris, AL; Knies-Bamforth, UE; Poulsom, R	1
Kohno, T; Konno, R; Machida, S; Mizuno, I; Ohwada, M; Saga, Y; Suzuki, M; Takayama, T; Takei, Y	1
Advani, AS	1
Abbruzzese, JL; Davis, DW; Demetri, GD; Herbst, RS; Heymach, JV; McConkey, DJ; Rashid, A; Raut, CP; Shen, Y; Stadler, WM; Takamori, R; Wen, S; Xiong, HQ	1
Capelle, HH; Erber, R; Farhadi, MR; Ullrich, A; Vajkoczy, P	1
du Manoir, J; Francia, G; Hicklin, DJ; Kerbel, RS; Ma, L; Rak, J; Viloria-Petit, A	1
Chowbay, B; Lye, KY; Moore, S; Olivo, M; Sharma, A; Zhou, Q	1
Blencke, S; Brehmer, D; Cotten, M; Daub, H; Degen, H; Eickhoff, J; Godl, K; Gruss, OJ; Horváth, Z; Kéri, G; Müller, S; Orfi, L; Ullrich, A; Weber, M; Wissing, J	1
Chikahisa, LM; Hasegawa, H; Kitajima, M; Kubota, T; Ozawa, S; Watanabe, M; Yamada, Y; Yorozuya, K	1
Devlin, J; Gorelik, E; Huang, X; Krasinskas, A; Lokshin, A; Raskovalova, T; Watkins, S; Wolf, SF	1
Giaccone, G; Hoekman, K; Kok, A; Kuenen, BC; Pinedo, HM; Ruijter, R; Schalkwijk, C	1
Elitzsch, A; Laschke, MW; Menger, MD; Vajkoczy, P; Vollmar, B	1
Kitagawa, Y; Kitajima, M; Kubota, T; Nakamura, T; Ozawa, S; Ueda, M	1
Fu, A; Hallahan, DE; Huamani, J; Kim, DW	1
Gianni, L; Grasselli, G; Ielmini, N; Lladò, A; Locatelli, A; Marimon, I; Marsoni, S; Sessa, C; Trigo, J; Viganò, L	1
Bani, MR; Borsotti, P; Cassis, L; Eccles, SA; Garofalo, A; Giavazzi, R; Naumova, E; Riccardi, E; Scanziani, E; Ubezio, P	1
Katoh, M	1
Chung, HK; Hwang, JH; Jo, KW; Jo, YS; Jung, HS; Kim, DW; Kweon, GR; Lee, SJ; Park, KC; Park, SH; Rha, SY; Shong, M; Song, JH	1
Jiang, XT; Tao, HQ; Zou, SC	1
Fukata, S; Iiyama, T; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Shuin, T	1
Abdollahi, A; Bertl, E; Ewerbeck, V; Gebhard, MM; Huber, PE; Klenke, FM; Sckell, A	1
Boschi, F; D'Onofrio, M; Faccioli, N; Marzola, P; Pozzi Mucelli, R; Sbarbati, A	1
Kitamura, R; Nagayama, S; Otagiri, M; Yamamoto, Y	1
Grosicka, A; Grosicki, S; Hołowiecki, J	1
Boonyarat, C; Grierson, DS; Kammasud, N; Saiki, I; Sakurai, H; Tsunoda, S; Vajragupta, O	1
Asanoma, H; Kitamura, R; Nagayama, S; Otagiri, M	1
Abdollahi, A; Debus, J; Hauser, K; Huber, PE; Lipson, KE; Roth, A; Timke, C; Weber, KJ; Zieher, H	1
Chu, ZH; Luo, XJ; Zeng, QL; Zhou, K	1
Baba, M; Hiramatsu, Y; Kamiya, K; Kawabata, T; Kikuchi, H; Kitagawa, M; Kondo, K; Konno, H; Ohta, M; Tanaka, T; Yamamoto, M	1
André, I; Boonyarat, C; Grierson, DS; Kammasud, N; Saiki, I; Sakurai, H; Sanphanya, K; Tsunoda, S; Utsintong, M; Vajragupta, O	1
Kitamura, R; Matsuoka, K; Nagayama, S; Otagiri, M	1
Calderan, L; Daducci, A; Degrassi, A; Farace, P; Galiè, M; Marzola, P; Merigo, F; Nicolato, E; Pesenti, E; Sbarbati, A	1
Gerhard, M; Kalali, B; Mempel, M; Ollert, M; Ring, J; Seidl, B	1
Stang, JL; Tran, LM; Zhong, H	1
Baba, M; Hiramatsu, Y; Kamiya, K; Kawabata, T; Kikuchi, H; Konno, H; Ohta, M; Tanaka, T; Yamamoto, M	1
Arioka, H; Ikeda, M; Kanai, F; Kawabe, T; Kondo, Y; Morizane, C; Obi, S; Okusaka, T; Omata, M; Sato, S; Shiina, S; Tagawa, K; Taniguchi, M; Tateishi, R; Yoshida, H	1
Arioka, H; Murakami, H; Shimoyama, T; Tamura, T; Ueda, Y; Yamada, Y; Yamamoto, N	2
Choi, SH; Chung, JW; Im, SA; Jae, HJ; Jun, S; Kim, HC; Park, JH; Yamasaki, Y	1
Khoo, CP; Micklem, K; Watt, SM	1
Ahn, JB; Chung, HC; Jeung, HC; Jung, M; Kim, HR; Rha, SY; Roh, JK; Shin, SJ	1
Chen, X; Hara, M; Ikeda, S; Kamijo, S; Kawasaki, J; Ogawa, H; Okumura, K; Takai, T; Ushio, H; Vu, AT; Xie, Y	1
Enooku, K; Goto, T; Kanai, F; Koike, K; Kondo, Y; Masuzaki, R; Omata, M; Shiina, S; Tateishi, R; Yoshida, H	1
Hokoda, N; Kasahara, K; Kitamura, R; Miyazaki, M; Nakagawa, K; Nakayama, H; Ohyama, A; Okamoto, I; Satouchi, M; Seto, T; Takeda, K; Yamamoto, N; Yoshihara, E; Yoshioka, H	1
Gangjee, A; Ihnat, MA; Raghavan, S; Thorpe, JE; Yang, J; Zaware, N	1
Aogi, K; Arioka, H; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Sato, Y; Takatsuka, Y; Toi, M; Tokuda, Y	1
Akiyama, S; Dat, le T; Goto, H; Hanibuchi, M; Kakiuchi, S; Kuramoto, T; Nishioka, Y; Sakaguchi, S; Sato, S; Sone, S; Van, TT; Yukishige, S	1
Aogi, K; Arioka, H; Fujii, H; Fujiwara, Y; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Suzuki, Y; Takatsuka, Y; Toi, M; Tokuda, Y; Watanabe, T	1
Al-awar, R; Fladd, C; Jiang, C; Nguyen, L; Prakesch, M; Rotin, D; Trzcinska-Daneluti, AM; Uehling, D	1
Chaton, CT; Herr, AB; Li, P; Mishra, A; Peng, J; Sankaran, B; Shu, C	1
Arai, Y; Aramaki, T; Arioka, H; Imanaka, K; Inaba, Y; Kanai, F; Kaneko, S; Kawai, N; Kora, S; Kudo, M; Matsui, O; Nishida, N; Seki, H; Tanaka, T; Yamakado, K; Yamamoto, T	1
Baba, H; Esaki, T; Fuse, N; Gotoh, M; Hara, T; Hosaka, H; Koizumi, W; Muro, K; Nakayama, N; Nishina, T; Sasaki, T; Sasaki, Y; Takagi, M; Takinishi, Y; Yamaguchi, K	1
Kasak, L; Kauts, ML; Loog, M; Neuman, T; Piirsoo, A; Piirsoo, M; Tints, K; Uusen, P	1
Choi, YJ; Chun, HG; Chung, HC; Chung, IJ; Han, SW; Kim, JG; Kim, SY; Kim, TW; Kim, YH; Lee, J; Shin, DB; Shin, SJ; Song, HS	1
Ahn, JH; Chung, HC; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, JH; Kim, SB; Park, HS; Ro, J; Song, HS; Yoo, C	2
Arioka, H; Asaoka, Y; Ikeda, M; Koike, K; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sakamoto, Y; Shiina, S; Shimizu, S; Tateishi, R; Ueno, H	1
Asahina, Y; Hara, Y; Hashiba, T; Hayashi, T; Honda, M; Kaneko, S; Kondo, M; Nio, K; Nomura, Y; Oishi, N; Okada, H; Sunagozaka, H; Yamashita, T; Yoshida, M	1
Ahn, JH; Chung, HC; Im, SA; Im, YH; Jung, KH; Kim, J; Kim, SB; Lee, KS; Park, HS; Ro, J; Sohn, BS; Song, HS	1
Chen, H; Li, H; Liu, C; Qian, B; Yao, Y; Zhang, J	1
Cai, C; Lei, J; Liu, QH; Shen, J; Tan, H; Xue, L	1
Arai, Y; Arioka, H; Cheng, AL; Chiu, CF; Heo, J; Hidaka, H; Izumi, N; Kudo, M; Lee, YJ; Liang, PC; Morita, S; Park, JH; Park, JW; Sheen, IS	1
Bhadoria, R; Eek, P; Kasak, L; Kasvandik, S; Näks, M; Piirsoo, A; Piirsoo, M; Saarma, M; Starkov, P	1
Arai, Y; Aramaki, T; Arioka, H; Furuse, J; Hidaka, H; Ikeda, M; Imanaka, K; Inaba, Y; Izumi, N; Kanazawa, S; Kaneko, S; Kora, S; Kudo, M; Matsui, O; Morita, S; Okusaka, T; Saito, H; Yamashita, T; Yokosuka, O	1

Reviews

8 review(s) available for pyrroles and orantinib

Article	Year
[Tumor angiogenesis and tumor angiogenesis inhibitors]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:5 Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1	2001
Su-6668. SUGEN. Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:8 Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Indoles; Neoplasms; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Structure-Activity Relationship	2001
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6 Topics: Angiogenesis Inhibitors; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasms; Oxindoles; Piperazines; Propionates; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles	2002
A targeted approach for antiangiogenic therapy of metastatic human colon cancer. The American surgeon, 2003, Volume: 69, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Colonic Neoplasms; Colorectal Neoplasms; Endothelial Growth Factors; Extracellular Matrix; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; Lymphokines; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Vascular endothelial growth factor in esophageal cancer. Journal of surgical oncology, 2004, Aug-01, Volume: 87, Issue:2 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Barrett Esophagus; Bevacizumab; Carcinoma, Squamous Cell; Esophageal Neoplasms; Humans; Indoles; Lymphangiogenesis; Neovascularization, Pathologic; Oxindoles; Prognosis; Propionates; Protein-Tyrosine Kinases; Pyrroles; RNA, Catalytic; RNA, Messenger; Vascular Endothelial Growth Factor A	2004
C-kit as a target in the treatment of acute myelogenous leukemia. Current hematology reports, 2005, Volume: 4, Issue:1 Topics: Acute Disease; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Clinical Trials as Topic; Hematopoiesis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid; Mice; Oxindoles; Piperazines; Propionates; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Stem Cell Factor	2005
FGF signaling network in the gastrointestinal tract (review). International journal of oncology, 2006, Volume: 29, Issue:1 Topics: Amino Acid Sequence; Animals; Base Sequence; Colon; Fibroblast Growth Factors; Gastric Mucosa; Gene Expression Regulation, Neoplastic; Humans; Indoles; Molecular Sequence Data; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Receptors, Fibroblast Growth Factor; Recombinant Proteins; Signal Transduction; Stomach Neoplasms; Stomatitis; Wnt Proteins	2006
[Clinical importance of angiogenesis and angiogenic factors in oncohematology]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2007, Volume: 60, Issue:1-2 Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiopoietin-1; Angiopoietin-2; Hematologic Neoplasms; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neovascularization, Pathologic; Oxindoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Propionates; Pyrroles; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factors	2007

Trials

19 trial(s) available for pyrroles and orantinib

Article	Year
Validation of liquid chromatography assay for the quantitation of (Z)-3-[2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid (SU006668) in human plasma and its application to a phase I clinical trial. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003, Feb-25, Volume: 785, Issue:1 Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Indoles; Oxindoles; Propionates; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet	2003
A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Investigational new drugs, 2004, Volume: 22, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Endpoint Determination; Female; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Oxindoles; Propionates; Pyrroles; Time Factors; Tomography, X-Ray Computed	2004
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:6 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Anthracenes; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Screening Assays, Antitumor; Gene Expression; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplasms, Experimental; Oxindoles; Perylene; Photochemotherapy; Propionates; Protein-Tyrosine Kinases; Proteins; Pyrroles; Survival Rate	2005
Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles	2005
Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:2 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; Humans; Indoles; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oxindoles; Propionates; Protein Binding; Pyrroles	2006
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:2 Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Area Under Curve; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Necrosis; Oxindoles; Propionates; Pyrroles; Survival Analysis; Treatment Outcome; Vascular Cell Adhesion Molecule-1	2011
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Oxindoles; Plasminogen Activator Inhibitor 1; Postprandial Period; Propionates; Protein-Tyrosine Kinases; Pyrroles; Vascular Endothelial Growth Factor A	2011
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Oxindoles; Postprandial Period; Propionates; Protein-Tyrosine Kinases; Pyrroles	2011
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Investigational new drugs, 2012, Volume: 30, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Combinations; Female; Fibroblast Growth Factors; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxindoles; Oxonic Acid; Platelet-Derived Growth Factor; Propionates; Protein Kinase Inhibitors; Pyrroles; Tegafur; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2	2012
Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times. Journal of gastroenterology, 2012, Volume: 47, Issue:1 Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Precursors; Prothrombin; Pyrroles; Time Factors; Treatment Outcome; Tumor Burden	2012
Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Oxindoles; Paclitaxel; Propionates; Pyrroles; Tissue Distribution; Treatment Outcome; Young Adult	2012
A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Breast cancer (Tokyo, Japan), 2014, Volume: 21, Issue:1 Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Indoles; Middle Aged; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A	2014
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. International journal of clinical oncology, 2013, Volume: 18, Issue:4 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A	2013
A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Humans; Indoles; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Oxindoles; Propionates; Proportional Hazards Models; Pyrroles; Time Factors; Treatment Outcome	2013
Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer. British journal of cancer, 2013, Oct-15, Volume: 109, Issue:8 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Combinations; Female; Humans; Indoles; Male; Middle Aged; Oxindoles; Oxonic Acid; Propionates; Pyrroles; Stomach Neoplasms; Survival Rate; Tegafur	2013
A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Investigational new drugs, 2014, Volume: 32, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; C-Reactive Protein; Colorectal Neoplasms; Disease-Free Survival; Drug Combinations; Female; Humans; Indoles; Interleukin-6; Interleukin-8; L-Lactate Dehydrogenase; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxindoles; Oxonic Acid; Platelet-Derived Growth Factor; Propionates; Proto-Oncogene Proteins c-sis; Pyrroles; Tegafur; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A	2014
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial. Investigational new drugs, 2014, Volume: 32, Issue:4 Topics: Adult; Aged; Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Indoles; Middle Aged; Oxindoles; Propionates; Pyrroles; Taxoids	2014
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. Investigational new drugs, 2014, Volume: 32, Issue:5 Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Oxindoles; Oxonic Acid; Propionates; Pyrroles; Tegafur; Treatment Outcome	2014
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Double-Blind Method; Early Termination of Clinical Trials; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Survival Analysis; Treatment Outcome	2018

Other Studies

65 other study(ies) available for pyrroles and orantinib

Article	Year
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer research, 2000, Aug-01, Volume: 60, Issue:15 Topics: 3T3 Cells; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Crystallography, X-Ray; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Indoles; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous; Tumor Cells, Cultured	2000
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood, 2001, Mar-01, Volume: 97, Issue:5 Topics: Angiogenesis Inhibitors; Apoptosis; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Humans; Indoles; Leukemia, Myeloid; Mitogen-Activated Protein Kinases; Oxindoles; Phosphorylation; Propionates; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrroles; Stem Cell Factor; Tumor Cells, Cultured	2001
Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer research, 2001, Feb-15, Volume: 61, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Division; Cell Survival; Colonic Neoplasms; Endothelium, Vascular; Indoles; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2001
Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer research, 2001, May-01, Volume: 61, Issue:9 Topics: Animals; Carcinoma, Small Cell; Cell Division; CHO Cells; Cricetinae; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Growth Inhibitors; Humans; Indoles; Lung Neoplasms; Models, Molecular; Oxindoles; Phosphorylation; Propionates; Proto-Oncogene Proteins c-kit; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Stem Cell Factor; Structure-Activity Relationship; Tumor Cells, Cultured	2001
Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, Volume: 15, Issue:7 Topics: Animals; Anticoagulants; Apoptosis; Becaplermin; Cell Survival; Cells, Cultured; Culture Media, Conditioned; Endothelial Growth Factors; Endothelium, Vascular; Gene Expression Regulation; Humans; Indoles; Lymphokines; Mice; Models, Biological; Muscle, Smooth, Vascular; Oxindoles; Paracrine Communication; Platelet-Derived Growth Factor; Propionates; Proto-Oncogene Proteins c-sis; Pyrroles; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2001
In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer research, 2001, Oct-01, Volume: 61, Issue:19 Topics: Androstadienes; Angiogenesis Inhibitors; Biomarkers, Tumor; Blotting, Western; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Fluorescent Antibody Technique; Humans; Indoles; Liver Neoplasms; Lymphokines; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Propionates; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wortmannin	2001
The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiation research, 2002, Volume: 157, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Indoles; Lymphokines; Mice; Mice, Inbred C3H; Neoplasm Proteins; Oxindoles; Platelet-Derived Growth Factor; Propionates; Pyrroles; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; RNA, Neoplasm; Specific Pathogen-Free Organisms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002
Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer research, 2002, Mar-15, Volume: 62, Issue:6 Topics: Animals; Cell Division; Chemotherapy, Adjuvant; Female; Fibrosarcoma; Humans; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred A; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Nude; Oxindoles; Pancreatic Neoplasms; Propionates; Pyrroles; Radiation-Sensitizing Agents; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2002
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2002, Volume: 16, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Blood Vessels; Cell Division; Dose-Response Relationship, Drug; Humans; Indoles; Kinetics; Mice; Mice, Nude; Neoplasms, Experimental; Oxindoles; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2002
Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668. The American journal of pathology, 2002, Volume: 160, Issue:6 Topics: Angiogenesis Inhibitors; Antigens, CD; Cadherins; Cell Adhesion; Cell Movement; Cells, Cultured; Chemokine CCL2; Chemokine CCL4; Chemokine CCL5; Chemokine CXCL12; Chemokines, CXC; Complement C5a; Down-Regulation; E-Selectin; Endothelial Growth Factors; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Humans; Indoles; Intercellular Adhesion Molecule-1; Lymphokines; Macrophage Inflammatory Proteins; Monocytes; Oxindoles; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Pyrroles; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wound Healing	2002
Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein. Cancer research, 2002, Oct-15, Volume: 62, Issue:20 Topics: Angiogenesis Inhibitors; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B7-2 Antigen; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Immunoglobulin G; Indoles; Interferon-gamma; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Mammary Neoplasms, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Recombinant Fusion Proteins; Spleen	2002
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents. Angiogenesis, 2002, Volume: 5, Issue:1-2 Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Isoflavones; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Quinoxalines	2002
Interleukin-2 and cancer: critical analysis of results, problems and expectations. Medical hypotheses, 2003, Volume: 60, Issue:2 Topics: Cytokines; Humans; Immunotherapy; Indoles; Interleukin-2; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Interleukin-2	2003
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. The Journal of clinical investigation, 2003, Volume: 111, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Islet Cell; Endothelium, Vascular; Female; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor	2003
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer research, 2003, Jul-01, Volume: 63, Issue:13 Topics: Angiogenesis Inhibitors; Cell Division; Cells, Cultured; Dose-Response Relationship, Radiation; Endothelial Growth Factors; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Kinetics; Lymphokines; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Oxindoles; Particle Accelerators; Propionates; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; X-Rays	2003
Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4 Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Fibroblasts; Humans; Immunohistochemistry; Indoles; Metalloproteases; Neoplasm Invasiveness; Neoplasms; Oxindoles; Paclitaxel; Propionates; Protease Inhibitors; Pyrroles; Stromal Cells	2003
SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis. Medical hypotheses, 2003, Volume: 61, Issue:2 Topics: Bone Marrow; Enzyme Inhibitors; Humans; Indoles; Models, Biological; Neovascularization, Pathologic; Oxindoles; Primary Myelofibrosis; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases	2003
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-15, Volume: 9, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Oxindoles; Paclitaxel; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2	2003
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:2 Topics: Animals; Apoptosis; Cell Survival; Hypoxia; Indoles; Microcirculation; Models, Biological; Neoplasms; Neovascularization, Pathologic; Oxindoles; Pericytes; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2004
In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Contrast Media; Humans; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Models, Statistical; Neoplasm Transplantation; Neovascularization, Pathologic; Oxindoles; Permeability; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Protein-Tyrosine Kinases; Pyrroles; Time Factors	2004
Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. International journal of radiation oncology, biology, physics, 2004, Mar-01, Volume: 58, Issue:3 Topics: Animals; Carcinoma, Lewis Lung; Cell Line, Tumor; Drug Evaluation, Preclinical; Endothelium, Vascular; Enzyme Activation; Humans; Indoles; Mice; Mice, Inbred C57BL; Oxindoles; Phosphorylation; Propionates; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor Protein-Tyrosine Kinases	2004
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer research, 2004, Sep-15, Volume: 64, Issue:18 Topics: Animals; Cell Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Keratinocytes; Mice; Neovascularization, Physiologic; Oxindoles; Papilloma; Precancerous Conditions; Propionates; Proto-Oncogene Proteins c-myc; Pyrroles; RNA, Messenger; Skin; Skin Neoplasms; Tamoxifen; Transcription Factors; Transgenes; Vascular Endothelial Growth Factor A	2004
Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). International journal of cancer, 2005, Mar-20, Volume: 114, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Metastasis; Ovarian Neoplasms; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Survival Analysis; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2005
Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-15, Volume: 11, Issue:2 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Oxindoles; Pancreatic Neoplasms; Phosphorylation; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2	2005
Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas. Journal of neurosurgery, 2005, Volume: 102, Issue:2 Topics: Animals; Apoptosis; Brain; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Transformation, Neoplastic; Glioma; Indoles; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Microscopy, Video; Neoplasm Transplantation; Neovascularization, Pathologic; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Rats; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2005
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer research, 2005, Jun-15, Volume: 65, Issue:12 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gemcitabine; Humans; Indoles; Oxindoles; Piperidines; Propionates; Pyrroles; Quinazolines; Thromboplastin	2005
Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer research, 2005, Aug-01, Volume: 65, Issue:15 Topics: Angiogenesis Inhibitors; Animals; Aurora Kinases; Cell Division; Chlorocebus aethiops; COS Cells; HeLa Cells; Humans; Indoles; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrroles; Transfection	2005
TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis. Oncology reports, 2005, Volume: 14, Issue:3 Topics: Administration, Oral; Animals; Cell Line, Tumor; Colonic Neoplasms; HT29 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Oxindoles; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Protein-Tyrosine Kinases; Pyrroles; Treatment Outcome; Xenograft Model Antitumor Assays	2005
Combined antiangiogenic and immune therapy of prostate cancer. Angiogenesis, 2005, Volume: 8, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; Cell Line, Tumor; Immunoglobulin G; Immunotherapy; Indoles; Male; Mice; Oxindoles; Propionates; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Recombinant Fusion Proteins; T-Lymphocytes	2005
Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Human reproduction (Oxford, England), 2006, Volume: 21, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Capillaries; Cricetinae; Endometriosis; Endometrium; Female; Fibroblast Growth Factors; Indoles; Mesocricetus; Neovascularization, Pathologic; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein Kinase Inhibitors; Pyrroles; Uterine Diseases; Vascular Endothelial Growth Factor A	2006
Antiangiogenic agent SU6668 suppresses the tumor growth of xenografted A-431 cells. Oncology reports, 2006, Volume: 15, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Endothelium, Vascular; Esophageal Neoplasms; Humans; Indoles; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Oxindoles; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Pyrroles; Xenograft Model Antitumor Assays	2006
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. International journal of radiation oncology, biology, physics, 2006, Jan-01, Volume: 64, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Class I Phosphatidylinositol 3-Kinases; Combined Modality Therapy; Endothelial Cells; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Neoplasms; Neovascularization, Pathologic; Oxindoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Propionates; Pyrroles; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Sunitinib; Vascular Endothelial Growth Factor A	2006
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-15, Volume: 12, Issue:6 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line; Cell Line, Tumor; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Female; Immunohistochemistry; Indoles; Laminin; Mice; Mice, Nude; Myocytes, Smooth Muscle; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxindoles; Paclitaxel; Platelet Endothelial Cell Adhesion Molecule-1; Propionates; Protein-Tyrosine Kinases; Proteoglycans; Pyrroles; Xenograft Model Antitumor Assays	2006
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:10 Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Proliferation; Humans; Indoles; Mice; NIH 3T3 Cells; Oxindoles; Phosphorylation; Propionates; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrroles; STAT3 Transcription Factor; Sunitinib	2006
[Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2006, Volume: 9, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism; Fluorouracil; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Stomach Neoplasms	2006
Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. International journal of oncology, 2007, Volume: 30, Issue:4 Topics: Animals; Bone and Bones; Carcinoma, Renal Cell; Cell Proliferation; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Humans; Indoles; Kidney; Kidney Neoplasms; Loss of Heterozygosity; Mice; Mutation; Oxindoles; Propionates; Pyrroles; Radiography; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein	2007
Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC cancer, 2007, Mar-17, Volume: 7 Topics: Angiogenesis Inhibitors; Animals; Chondrosarcoma; Disease Models, Animal; Indoles; Injections, Subcutaneous; Male; Mice; Mice, SCID; Microcirculation; Oxindoles; Propionates; Pyrroles; Treatment Outcome	2007
Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging. La Radiologia medica, 2007, Volume: 112, Issue:3 Topics: Adenocarcinoma; Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Colonic Neoplasms; Contrast Media; Gadolinium DTPA; Indoles; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Microcirculation; Neoplasms, Experimental; Organometallic Compounds; Oxindoles; Propionates; Protein-Tyrosine Kinases; Pyrroles; Rats; Tamoxifen	2007
Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) during oral administration twice a day to rats. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:9 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Area Under Curve; Bile; Chromatography, High Pressure Liquid; In Vitro Techniques; Indoles; Injections, Intravenous; Intestinal Absorption; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Oxidation-Reduction; Oxindoles; Propionates; Pyrroles; Rats; Rats, Sprague-Dawley	2007
Novel inhibitor for fibroblast growth factor receptor tyrosine kinase. Bioorganic & medicinal chemistry letters, 2007, Sep-01, Volume: 17, Issue:17 Topics: Chemistry, Pharmaceutical; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Fibroblast Growth Factor 1; Humans; Hydrogen Bonding; Indoles; JNK Mitogen-Activated Protein Kinases; Lysine; Models, Chemical; Molecular Conformation; Oxindoles; Propionates; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1	2007
Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68). Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:6 Topics: Angiogenesis Inhibitors; Cells, Cultured; Cytochrome P-450 Enzyme System; Glucuronides; Hepatocytes; Humans; Hydroxylation; Indoles; Microsomes, Liver; Oxindoles; Propionates; Protein Isoforms; Pyrroles	2008
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Apr-01, Volume: 14, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endothelial Cells; Flow Cytometry; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Radiation-Sensitizing Agents; Radiotherapy; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays	2008
[Effect of Endostatin and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2008, Volume: 11, Issue:4 Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colonic Neoplasms; Endostatins; Fluorouracil; Humans; Indoles; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles	2008
TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer research, 2008, Dec-01, Volume: 68, Issue:23 Topics: Animals; Cell Movement; Chemokine CXCL1; Colonic Neoplasms; Gene Expression Profiling; Humans; Indoles; Interleukin-12 Subunit p40; Liver; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Neutrophils; Oligonucleotide Array Sequence Analysis; Oxindoles; Propionates; Pyrroles; Receptors, Interleukin-8B; RNA, Messenger; Xenograft Model Antitumor Assays	2008
5-Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinases. Bioorganic & medicinal chemistry letters, 2009, Feb-01, Volume: 19, Issue:3 Topics: Cell Proliferation; Cells, Cultured; Chemistry, Pharmaceutical; Drug Design; Endothelium, Vascular; Enzyme Inhibitors; Fibroblast Growth Factor 2; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Oxindoles; Phosphorylation; Propionates; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Tyrosine	2009
Time-dependent induction of rat hepatic CYP1A1 and CYP1A2 expression after single-dose administration of the anti-angiogenic agent TSU-68. Drug metabolism and pharmacokinetics, 2008, Volume: 23, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Base Sequence; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Enzyme Induction; Gene Expression Regulation, Enzymologic; Indoles; Male; Microsomes, Liver; Molecular Sequence Data; Oxindoles; Propionates; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Time Factors	2008
Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas. British journal of cancer, 2009, May-19, Volume: 100, Issue:10 Topics: Animals; Carcinoma; Cell Proliferation; Colonic Neoplasms; Disease Progression; HT29 Cells; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases; Stromal Cells; Up-Regulation; Xenograft Model Antitumor Assays	2009
Thymic stromal lymphopoietin induction by polyinosinic:polycytidylic acid in human keratinocytes is preferentially mediated through protein kinase R and retinoid-inducible gene I and not Toll-like receptor 3. The Journal of allergy and clinical immunology, 2009, Volume: 124, Issue:4 Topics: 2-Aminopurine; Antimetabolites; Cells, Cultured; Cytokines; DEAD Box Protein 58; DEAD-box RNA Helicases; eIF-2 Kinase; Enzyme Inhibitors; Humans; Indoles; Interferon Inducers; Interferon-Induced Helicase, IFIH1; Keratinocytes; Macrolides; Oxindoles; Poly I-C; Propionates; Pyrroles; Receptors, Immunologic; Thymic Stromal Lymphopoietin; Toll-Like Receptor 3	2009
Induced-fit docking studies of the active and inactive states of protein tyrosine kinases. Journal of molecular graphics & modelling, 2009, Volume: 28, Issue:4 Topics: Binding Sites; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Hydrogen Bonding; Indoles; Ligands; Models, Molecular; Oxindoles; Propionates; Protein Structure, Secondary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrroles; Quinazolines; Reproducibility of Results; Sunitinib	2009
TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surgery today, 2009, Volume: 39, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Colon; Colonic Neoplasms; Disease Models, Animal; Drug Delivery Systems; Humans; Indoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Neovascularization, Physiologic; Oxindoles; Propionates; Pyrroles; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Sensitivity and Specificity; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2009
Augmentation of chemotherapeutic infusion effect by TSU-68, an oral targeted antiangiogenic agent, in a rabbit VX2 liver tumor model. Cardiovascular and interventional radiology, 2012, Volume: 35, Issue:1 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Doxorubicin; Drug Therapy, Combination; Ethiodized Oil; Indoles; Infusions, Intravenous; Liver Neoplasms, Experimental; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Rabbits; Statistics, Nonparametric; Tomography, X-Ray Computed	2012
A comparison of methods for quantifying angiogenesis in the Matrigel assay in vitro. Tissue engineering. Part C, Methods, 2011, Volume: 17, Issue:9 Topics: Angiogenesis Inhibitors; Biological Assay; Collagen; Colony-Forming Units Assay; Drug Combinations; Endothelial Cells; Endothelium, Vascular; Fetal Blood; Humans; Image Processing, Computer-Assisted; Indoles; Intercellular Signaling Peptides and Proteins; Laminin; Neovascularization, Physiologic; Oxindoles; Phenotype; Propionates; Proteoglycans; Pyrroles; Software; Suramin	2011
Extracellular double-stranded RNA induces TSLP via an endosomal acidification- and NF-κB-dependent pathway in human keratinocytes. The Journal of investigative dermatology, 2011, Volume: 131, Issue:11 Topics: Cells, Cultured; Cytokines; Endosomes; Humans; Indoles; Interferon Regulatory Factor-3; Interferon-beta; Interleukin-8; Keratinocytes; Macrolides; NF-kappa B; Oxindoles; Poly I-C; Propionates; Pyrroles; RNA, Double-Stranded; RNA, Small Interfering; Signal Transduction; Thymic Stromal Lymphopoietin; Toll-Like Receptor 3; Transcription Factor RelA	2011
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation. Bioorganic & medicinal chemistry, 2012, Apr-01, Volume: 20, Issue:7 Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Design; Humans; Indoles; Mice; Mice, Nude; Molecular Dynamics Simulation; Neoplasms; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2	2012
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. Respirology (Carlton, Vic.), 2012, Volume: 17, Issue:6 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factor 2; Humans; Indoles; Male; Mesothelioma; Mice; Mice, SCID; Neovascularization, Pathologic; Oxindoles; Pleural Effusion, Malignant; Pleural Neoplasms; Propionates; Protein Kinase Inhibitors; Pyrroles; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2012
Use of kinase inhibitors to correct ΔF508-CFTR function. Molecular & cellular proteomics : MCP, 2012, Volume: 11, Issue:9 Topics: Animals; Benzazepines; Cell Line; Cricetinae; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Dogs; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HEK293 Cells; Humans; Indoles; Ion Transport; Membrane Proteins; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Transport; Protein-Tyrosine Kinases; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA Interference; RNA, Small Interfering; Sequence Deletion; Signal Transduction; Zearalenone	2012
Structural insights into the functions of TBK1 in innate antimicrobial immunity. Structure (London, England : 1993), 2013, Jul-02, Volume: 21, Issue:7 Topics: Amino Acid Sequence; Animals; Bacterial Infections; Catalytic Domain; Crystallography, X-Ray; Enzyme Activation; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Immunity, Innate; Indoles; Interferon Regulatory Factor-3; Mice; Models, Molecular; Molecular Sequence Data; Oxindoles; Phosphorylation; Propionates; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Protein Multimerization; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Quaternary; Protein Structure, Secondary; Pyrroles; Structural Homology, Protein	2013
Protein kinase inhibitor SU6668 attenuates positive regulation of Gli proteins in cancer and multipotent progenitor cells. Biochimica et biophysica acta, 2014, Volume: 1843, Issue:4 Topics: Animals; Cell Differentiation; Cells, Cultured; Gene Expression Regulation, Developmental; Hedgehog Proteins; Humans; Indoles; Kruppel-Like Transcription Factors; Leukocytes, Mononuclear; Mice; Multipotent Stem Cells; Neoplasms; Nuclear Proteins; Oxindoles; Propionates; Protein Serine-Threonine Kinases; Pyrroles; Signal Transduction; Transcription Factors; Transforming Growth Factor beta; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2	2014
TSU-68 ameliorates hepatocellular carcinoma growth by inhibiting microenvironmental platelet-derived growth factor signaling. Anticancer research, 2015, Volume: 35, Issue:3 Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Mice; Oxindoles; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Transforming Growth Factor beta1	2015
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. Cancer research and treatment, 2016, Volume: 48, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; C-Reactive Protein; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factors; Humans; Indoles; Interleukin-6; Middle Aged; Neoplasm Metastasis; Oxindoles; Propionates; Pyrroles; Taxoids; Vascular Endothelial Growth Factor A	2016
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline. Asia-Pacific journal of clinical oncology, 2017, Volume: 13, Issue:6 Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Oxindoles; Propionates; Pyrroles; Quality of Life; Taxoids	2017
SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway. International journal of oncology, 2017, Volume: 50, Issue:5 Topics: Angiogenesis Inhibitors; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Membrane Proteins; Neoplasm Invasiveness; Oxindoles; Propionates; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; RNA-Binding Proteins; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2	2017
Relaxing Effect of TSU-68, an Antiangiogenic Agent, on Mouse Airway Smooth Muscle. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 41, Issue:6 Topics: Acetylcholine; Angiogenesis Inhibitors; Animals; Calcium; Calcium Channels; Cells, Cultured; Indoles; Male; Mice; Mice, Inbred BALB C; Muscle Contraction; Muscle Relaxation; Myocytes, Smooth Muscle; Oxindoles; Patch-Clamp Techniques; Potassium; Propionates; Pyrroles	2017
Characterization of Protein Kinase ULK3 Regulation by Phosphorylation and Inhibition by Small Molecule SU6668. Biochemistry, 2018, 09-18, Volume: 57, Issue:37 Topics: Amino Acid Sequence; Catalytic Domain; Gene Expression Regulation, Enzymologic; Humans; Indoles; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Oxindoles; Phosphorylation; Propionates; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrroles; Sequence Homology; Signal Transduction	2018
Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). Medical oncology (Northwood, London, England), 2019, May-03, Volume: 36, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Humans; Indoles; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Survival Rate; Treatment Outcome	2019